Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse

Table 4 Multivariable Cox regression survival analysis of factors associated with risk of relapse

Variable	Hazard ratio (95% CI)	p
ANCA status at switch to maintenance therapy
ANCA-positive	1	0.026
ANCA-negative	0.63 (0.42–0.95)	0.026
ANCA specificity at trial entry
MPO-ANCA	1	0.005
PR3-ANCA	1.87 (1.21–2.89)	0.005
Initial induction treatment
Daily oral cyclophosphamide	1	0.045
Pulsed cyclophosphamide	1.52 (1.01–2.29)	0.045
Creatinine at entry (per 50 μmol/L)	0.89 (0.83–0.97)	0.004
Initial maintenance therapy
AZA	1	0.002
MMF	2.08 (1.38–3.13)	0.002
Age (per decade)	0.88 (0.76–1.01)	0.065
Gender	0.98 (0.65–1.49)	0.93
Time to remission	1.0 (0.87–1.15)	0.97

ANCA anti-neutrophil cytoplasm antibodies, AZA azathioprine, CI confidence interval, MMF mycophenolate mofetil, MPO myeloperoxidase, PR3 proteinase 3

ISSN: 1478-6362